A detailed history of Profund Advisors LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 19,038 shares of NRIX stock, worth $380,379. This represents 0.02% of its overall portfolio holdings.

Number of Shares
19,038
Previous 25,588 25.6%
Holding current value
$380,379
Previous $534,000 20.04%
% of portfolio
0.02%
Previous 0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$18.93 - $25.69 $123,991 - $168,269
-6,550 Reduced 25.6%
19,038 $427,000
Q2 2024

Aug 13, 2024

SELL
$12.02 - $21.3 $89,813 - $159,153
-7,472 Reduced 22.6%
25,588 $534,000
Q1 2024

May 08, 2024

BUY
$7.77 - $15.66 $256,876 - $517,719
33,060 New
33,060 $485,000
Q3 2023

Nov 13, 2023

SELL
$7.86 - $10.08 $31,565 - $40,481
-4,016 Reduced 18.9%
17,233 $135,000
Q2 2023

Aug 10, 2023

SELL
$8.7 - $13.28 $44,457 - $67,860
-5,110 Reduced 19.39%
21,249 $212,000
Q1 2023

May 11, 2023

BUY
$8.56 - $13.26 $225,633 - $349,520
26,359 New
26,359 $234,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $942M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.